Shingles vaccine: GSK submits Biologics License Application for Shingrix
by Press Release from Outbreak News Today on (#1ZDKP)
GlaxoSmithKline announced this week that it has submitted a Biologics License Application (BLA) for its candidate shingles vaccine, ShingrixTM, to the United States Food and Drug Administration (FDA), seeking approval for the prevention of herpes zoster (shingles) in people aged 50 years or over. The candidate vaccine is a non-live, recombinant vaccine to help prevent shingles ["]
